PSYENCE BIOMEDICAL

Psyence Biomedical has treated the first patient in a randomized, double-blind phase IIb trial of NPX-5 (25 mg natural psilocybin) for adjustment disorders in cancer patients receiving palliative care. The study includes three dosing levels and is being conducted at five clinics in Australia, aiming to assess safety, efficacy, tolerability and durability of the treatment. The results are intended to inform the company's further development strategy and potential regulatory pathways. » More on de.investing.com

Psyence Biomedical has expanded its network for the ongoing phase IIb study in Australia from three to five sites, adding Ramsay Health Care and NeuroCentrix to accelerate recruitment and multicenter enrollment. The study of NPX-5, a pharmaceutical psilocybin candidate, investigates treatment of adjustment disorders in cancer patients receiving palliative care; first patient dosing began in late 2025. NPX-5 is manufactured in capsules (1 mg and 5 mg) at PsyLabs’ GMP-controlled production facility, in which Psyence has made a strategic investment. The company notes high cash burn despite a strong current ratio and has not yet obtained approval or demonstrated efficacy/safety for its drug candidates; market capitalization is small and the share price has fallen sharply. » More on de.investing.com